Marker Therapeutics (NASDAQ:MRKR) Posts Earnings Results, Beats Expectations By $0.17 EPS

Marker Therapeutics (NASDAQ:MRKR) announced its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.17, FiscalAI reports. The business had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%.

Marker Therapeutics Stock Performance

Shares of MRKR stock traded down $0.02 during trading hours on Wednesday, reaching $1.34. The company had a trading volume of 73,038 shares, compared to its average volume of 328,445. The business has a fifty day moving average price of $1.63 and a 200-day moving average price of $1.29. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07. The firm has a market cap of $22.34 million, a PE ratio of -1.09 and a beta of 1.42.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MRKR shares. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. Zacks Research cut Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. HC Wainwright began coverage on Marker Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. Finally, Wall Street Zen raised Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Marker Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Institutional Investors Weigh In On Marker Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new stake in Marker Therapeutics during the fourth quarter valued at about $222,000. XTX Topco Ltd boosted its stake in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after acquiring an additional 36,269 shares during the period. Osaic Holdings Inc. grew its position in shares of Marker Therapeutics by 16.5% during the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Marker Therapeutics during the fourth quarter worth about $60,000. Finally, Renaissance Technologies LLC raised its stake in Marker Therapeutics by 16.4% during the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after purchasing an additional 17,400 shares during the period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.